FDA Approved: BRYNOVIN — Original Application (Azurity Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved Brynovin as an original-application product containing sitagliptin hydrochloride for oral use, for the treatment of type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• BRYNOVIN (Sitagliptin hydrochloride)

Snippet

ORIG AP for BRYNOVIN (SITAGLIPTIN HYDROCHLORIDE ORAL)